European Study of Cardiovascular Risk (EURIKA)

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: April 15, 2009
Last updated: October 28, 2009
Last verified: October 2009

The main objective of this study is to describe the management of patients with cardiovascular risk factors in primary prevention among different European countries.

The patient's participation consists of a single study visit during a routine visit of the patient to the clinic/office.

Study variables will be measured:

  • By an interview between physician and patient during the visit and/or available medical records' information: social and demographic patient characteristics, relevant family medical history, current medication.
  • By questions asked to the physician: physician perception of patients' CV risk factor, guidelines adherence and cost-containment.
  • By measurement performed to the patient during the visit: weight, height, BMI, waist and hip circumference will be measured.
  • CV risk factors (blood parameters) will be measured by collecting available data documented within the last year in the medical records and by the collection and analyses of a blood sample during the visit.

Cardiovascular Risk Factors

Study Type: Observational
Study Design: Time Perspective: Cross-Sectional
Official Title: Epidemiological Study of European Cardiovascular Risk Patients: Disease Prevention and Management in Usual Daily Practice

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • LDL-cholesterol, systolic and diastolic blood pressure, Tot. cholesterol, Non-HDL cholesterol, HDL-cholesterol, waist and hip circumference, HbA1c [ Time Frame: Cross-sectional ] [ Designated as safety issue: No ]
  • Gender, age, patients with diabetes and/or hypertension (%), smoker status, family medical history. [ Time Frame: Cross-sectional ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • BMI, Score based 10 year CHD mortality > 5%, High Risk patients (no. and %) [ Time Frame: Cross-sectional ] [ Designated as safety issue: No ]
  • Use of concomitant medication: anticoagulant, anti hypertensive, antidiabetic, lipid-lowering drugs [ Time Frame: Cross-sectional ] [ Designated as safety issue: No ]
  • Biomarkers: Apo-A1, Apo-B, Hs-CRP, Creatinine, albuminuria, uric acid, glomerular filtration rate. [ Time Frame: Cross-sectional ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples Without DNA
Whole blood Serum

Estimated Enrollment: 7200
Study Start Date: May 2009
Study Completion Date: October 2009
Patients 50+ years old, with at least one additional CV risk factor (with no previous CV event or hospitalization for a CV event)


Ages Eligible for Study:   50 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients 50+ years old, with at least one additional CV risk factor (with no previous CV event or hospitalisation for a CV event) from Primary Care or hospital outpatient clinic.Participating investigators will belong either to PC centres or hospitals, in the proportion representing the reality on where this kind of patient is managed in each country.

Inclusion Criteria:

  • Provision of informed consent.
  • Patients 50+ years old, with at least one additional CV risk factor (with no previous CV event or hospitalisation for a CV event) from Primary Care or hospital outpatient clinic.

Exclusion Criteria:

  • Subjects who are unwilling or unable to provide informed consent
  • Previous CV disease event or hospitalisation for a CV event
  • Current participation in a clinical trial
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00882336

  Show 778 Study Locations
Sponsors and Collaborators
Study Director: Elvira Massó AstraZeneca Spain
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):

Responsible Party: MSD, AstraZeneca Identifier: NCT00882336     History of Changes
Other Study ID Numbers: NIS-CEU-DUM-2008/1 
Study First Received: April 15, 2009
Last Updated: October 28, 2009
Health Authority: Austria: Ethikkommission
Switzerland: Ethikkommission
Germany: Ethics Commission
Turkey: Ethics Committee
United Kingdom: Research Ethics Committee
United Kingdom: National Health Service
Belgium: Institutional Review Board
Sweden: Regional Ethical Review Board
Norway:National Committee for Medical and Health Research Ethics
France: Institutional Ethical Committee
France: French Data Protection Authority
Greece: Ethics Committee
Greece: Ministry of Health and Welfare
Spain: Ethics Committee
Russia: Ethics Committee

Keywords provided by AstraZeneca:
Cardiovascular risk management

Additional relevant MeSH terms:
Lipid Metabolism Disorders
Metabolic Diseases processed this record on April 27, 2016